Introduction to AI for High-Content Screening

High-content screening (HCS) is an advanced phenotypic screening technique that combines automated microscopy with quantitative image analysis to evaluate the effects of chemical or genetic perturbations on cells. Using high-content screening, researchers can extract multidimensional data, which indicate changes in morphology, protein expression, localization and metabolite levels, from thousands of cells simultaneously.¹

HCS plays a critical role in early-stage drug discovery, toxicology and systems biology. Unlike traditional assays focusing on a single endpoint, HCS provides comprehensive insights into cellular responses, helping identify subtle phenotypic changes. Another advantage of HCS is its compatibility with multiple cell and tissue models, including immortalized lines (e.g., HeLa, HEK293), primary cells and induced pluripotent stem cells (iPSCs).² More recently, 3D organoids cultivated in carefully controlled environments have gained attention for their ability to better mimic physiological environments.³

Although related, HCS and high-throughput screening (HTS) refer to different techniques. HCS and its high-content imaging (HCI) step provide multiparameter and in-depth information about cells through image-based phenotyping. On the other hand, HTS involves rapidly screening vast compound libraries against a single target in the cell to identify as many candidates as possible. Overall, while HTS is helpful for the straightforward identification of hits, HCS involves a more mechanistic investigation of cellular responses against these hits.³

Extracting meaningful quantitative information from the massive image datasets generated by HCS requires a computational approach called high-content analysis (HCA). Artificial intelligence (AI) plays a role in HCA by streamlining complex image analyses. Machine learning and deep learning methods improve segmentation and feature extraction in heterogeneous samples, facilitating clustering and pattern recognition across massive datasets. Thus, researchers can correlate cellular responses to therapeutic outcomes with reduced human bias and processing time, accelerating the evaluation of promising drug candidates.⁴

High Content Screening Techniques and Technologies

Imaging Modalities

High-content screening traditionally relies on fluorescence microscopy, where cellular components are tagged with fluorescent dyes or proteins to visualize biological processes such as protein localization, cell cycle progression or apoptosis. Furthermore, multiplexed fluorescence imaging allows simultaneous detection of multiple markers, providing rich, multidimensional datasets.¹

In contrast, label-free imaging, such as phase-contrast or brightfield microscopy, captures cellular morphology and dynamics without external probes. This approach simplifies sample preparation and minimizes phototoxicity, making it ideal for live-cell imaging and longitudinal studies.¹

Multiparametric imaging can enhance the dimensionality of image acquisition. Confocal microscopy, a key modality in HCS, enhances image resolution and depth discrimination by using optical sectioning to eliminate out-of-focus light. It is particularly useful in visualizing 3D cell models, such as spheroids or organoids, where spatial organization and intracellular localization are crucial for interpreting biological effects.⁵

AI-based image analysis for high-content screening allows the extraction of quantitative phenotypic features from these imaging modalities.¹

Image Analysis and Data Processing

Automation is central to AI-driven high-content workflows. Robotic microscopes, plate readers, liquid handlers and motorized stages streamline sample preparation and capture thousands of images per experiment with minimal human intervention. Collectively, these instruments ensure consistent exposure, focus and field of view across samples, which are critical for reproducible image analysis.⁶

Once images are captured, segmentation separates them into meaningful regions containing individual cells or subcellular structures using AI-based models like convolutional neural networks (CNNs). Hundreds of features can be extracted from these segmented regions, ranging from shape, size and texture to signal intensity and spatial organization. These quantitative features form the foundation for downstream statistical analysis and phenotype classification.⁷

Multiple imaging modalities, including fluorescence, brightfield and label-free phase imaging, can be combined to build a more complete picture of cellular behavior. Researchers can infer correlations between morphological, molecular and kinetic parameters by integrating images from these modalities. AI-driven techniques can harmonize and analyze these diverse datasets, revealing subtle cellular phenotypes that may go undetected in single-modality imaging.⁴

Nevertheless, reproducibility in HCS requires stringent image quality control through automated instrument calibration and data standardization. The adoption of open data standards, such as OME-TIFF and MIHCS) allows a more objective evaluation of image metadata^.8

Applications of AI in High-Content Screening

Artificial Intelligence has been widely used in high-content screening in several life sciences fields, including:⁴

• Drug Discovery and Development
• Phenotypic Screening
• Toxicology and Assessing Toxicity
• Disease Modeling
• Genomic and functional screening
• Biologics and antibody discovery

Phenotypic and Cellular Profiling

AI-powered high-content screening is instrumental in phenotypic profiling, enabling researchers to detect subtle cellular changes in response to compounds or genetic perturbations. While traditional phenotypic profiling solely relies on predefined biomarkers, machine learning model scan learn complex morphological patterns directly from image data. Thus, AI paves the way for unbiased phenotypic profiling, where cellular states are characterized based on global morphology, texture and spatial organization rather than predetermined markers.⁷

Implementing AI for high-content screening accelerates compound screening by rapidly analyzing large datasets to distinguish safe and active compounds from inactive or toxic ones. Machine learning algorithms can identify phenotypic signatures associated with desired therapeutic effects, helping researchers select and prioritize promising drug candidates early in the discovery process.⁹

Furthermore, AI models trained on high-content screening datasets can predict compound behavior across different cell types, allowing the extrapolation of insights beyond the initial screening conditions. This capability reduces the experimental burden required for different cell types while improving hit quality and downstream validation efficiency.⁴

Drug Discovery and Development

AI reduces image acquisition and data analysis timelines while establishing objective decision-making during drug discovery screening. AI algorithms help researchers refine high-content screening parameters based on preliminary results, ultimately optimizing screening workflow efficiency. This feedback-driven design streamlines hit identification, lead optimization and preclinical validation.⁴

Alongside hit identification, artificial intelligence can significantly contribute to assessing compound toxicity and efficacy during HCS. By correlating phenotypic patterns with known toxic or therapeutic outcomes, AI models can forecast biological responses of novel compounds to mitigate failures during animal testing or clinical trials.⁴ Some examples include:

• Deep learning-based toxicity prediction to determine morphological hallmarks of hepatotoxicity or cardiotoxicity¹⁰
• Predictive efficacy models that infer dose-response relationships based on phenotypic characteristics¹¹

AI-derived HCS data can seamlessly integrate into drug development pipelines, connecting in vitro cellular responses with multi-omics, preclinical and clinical datasets. By complementing omics-based and patient-derived data with insights from high-content imaging, pharmaceutical companies can better predict clinical outcomes and tailor therapies to specific disease subtypes, championing precision medicine research.¹²

Benefits of AI in High Content Screening in Drug Discovery

Given the utility of AI for several high-content screening applications, its benefits in drug discovery can be summarized as follows:⁴

• Enhanced Data Analysis: Machine learning and deep learning algorithms can uncover novel information from vast volumes of complex image data to elucidate cellular responses to therapeutic strategies
• Improved Drug Discovery Process: AI enhances the utility of image-based analysis in drug discovery pipelines, imparting researchers with a holistic overview of how a drug or perturbation alters the behavior of target cell populations
• Cost and Time Reduction: AI significantly reduces both time and cost by automating image classification, phenotype quantification and hit validation

Challenges and Limitations

Despite the many advantages, integrating AI into high-content screening introduces challenges to drug discovery pipelines.

AI performance in high-content screening heavily depends on the quality and consistency of input data. Sample preparation, imaging conditions and assay design variations can introduce biases and artifacts that degrade model accuracy. Therefore, establishing standardized imaging protocols is critical for generating reproducible data.¹³

Moreover, the lack of unified data formats across instruments and vendors complicates data sharing and model transferability. Many research facilities use proprietary imaging platforms that lack native AI integration or scalable data handling. To fully leverage AI, laboratories must optimize workflows by upgrading hardware infrastructure and software ecosystems and implementing secure data storage solutions for large datasets.¹³

The successful implementation of AI tools in HCS requires multidisciplinary expertise spanning biology, microscopy, data science and software engineering. However, research teams may lack personnel with the necessary computational skills to develop, validate and interpret AI models. Bridging this gap requires training programs, user-friendly analytical interfaces and collaboration between experimentalists and data scientists. ¹³

While AI accelerates image analysis, scaling these solutions to industrial-level screening remains complex. Large pharmaceutical operations often handle millions of data points daily, requiring high-performance computing infrastructure and optimized algorithms capable of maintaining speed without sacrificing accuracy.¹³

Finally, AI applications in drug discovery must comply with regulatory and industry standards. Reproducibility remains a critical concern, as AI models can be challenging to interpret when applied to new datasets or experimental conditions. Therefore, AI algorithms must be transparent, interpretable and validated under Good Laboratory Practice (GLP) frameworks to meet compliance expectations from the FDA or EMA.¹³

References

1. Lin S, Schorpp K, Rothenaigner I, Hadian K. Image-based high-content screening in drug discovery. Drug Discov Today 2020;25(8):1348-1361.
2. Lee OW, Austin S, Gamma M, Cheff DM, Lee TD, Wilson KM, et al. Cytotoxic profiling of annotated and diverse chemical libraries using quantitative high-throughput screening. Slas Discov 2020;25(1):9-20.
3. Lampart FL, Iber D, Doumpas N. Organoids in high-throughput and high-content screenings. Front Chem Eng 2023;5:1120348.
4. Carreras-Puigvert J, Spjuth O. Artificial intelligence for high content imaging in drug discovery. Curr Opin Struct Biol 2024;87:102842.
5. Rodriguez K, Saunier F, Rigaill J, Audoux E, Botelho-Nevers E, Prier A, et al. Evaluation of in vitro activity of copper gluconate against SARS-CoV-2 using confocal microscopy-based high content screening. J Trace Elem Med Bio 2021;68:126818.
6. Diosdi A, Toth T, Harmati M, Istvan G, Schrettner B, Hapek N, et al. HCS-3DX, a next-generation AI-driven automated 3D-oid high-content screening system. Nat Commun 2025;16(1):8897.
7. Schiff L, Migliori B, Chen Y, Carter D, Bonilla C, Hall J, et al. Integrating deep learning and unbiased automated high-content screening to identify complex disease signatures in human fibroblasts. Nat commun 2022;13(1):1590.
8. Massei R, Busch W, Serrano-Solano B, Bernt M, Scholz S, Nicolay EK, et al. High-content screening (HCS) workflows for FAIR image data management with OMERO. Sci Rep 2025;15(1):16236.
9. Chen X, Xun D, Zheng R, Zhao L, Lu Y, Huang J, et al. Deep-learning-assisted assessment of DNA damage based on foci images and its application in high-content screening of lead compounds. Anal Chem 2020;92(20):14267-14277.
10. Chen X, Liu C, Zhao H, Zhong Y, Xu Y, Wang Y. Deep learning-assisted high-content screening identifies isoliquiritigenin as an inhibitor of DNA double-strand breaks for preventing doxorubicin-induced cardiotoxicity. Biol Direct 2023;18(1):63.
11. Hu Y, Xue X, Han T, Li Y, Zhang T, Lu T, et al. An effective system for senescence modulating drug development using quantitative high-content analysis and high-throughput screening. Commun Biol 2025;8(1):1316.
12. Shafiq K. Multi-Omics and High-Content Screening for the Discovery of Plant Cyclic Peptides in Cancer Drug Development. 2025.
13. Hartung T, Kleinstreuer N. Challenges and opportunities for validation of AI-based new approach methods. ALTEX 2025;42(1):3-21.